Patents Examined by Sonya Wright
  • Patent number: 9884801
    Abstract: The invention relates to bioactive compounds purified from mycelium of Antrodia camphorata and the manufacturing method thereof. A method for treatment of cancers by administrating an effective amount of the said compounds selected from the group consisting of AC006, AC007, AC009, AC011, AC012, AC007-H1, AC009-H1, and AC012-H1 wherein the cancers is liver cancer, brain cancer, prostate cancer, breast cancer, colorectal cancer, or melanoma.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 6, 2018
    Assignee: Oneness Biotech Co., Ltd.
    Inventors: Chiung-Lin Liu, Wei-Tse Tsai, Kai-Hsin Hsieh
  • Patent number: 9862719
    Abstract: Spirocyclic cyclohexane compounds corresponding to formula I a method for producing them, pharmaceutical compositions containing them, and methods of using them.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: January 9, 2018
    Assignee: Gruenenthal GmbH
    Inventors: Claudia Hinze, Otto Aulenbacher, Bernd Sundermann, Stefan Oberboersch, Elmar Friderichs, Werner Englberger, Babette-Yvonne Koegel, Klaus Linz, Hans Schick, Helmut Sonnenschein, Birgitta Henkel, Valerie Sarah Rose, Michael Jonathan Lipkin
  • Patent number: 9856231
    Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 2, 2018
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Hoang V. Le, Dustin D. Hawker
  • Patent number: 9844531
    Abstract: Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 19, 2017
    Assignee: ABBOTT LABORATORIES
    Inventors: Sean Garvey, Suzette Pereira, Neile Edens
  • Patent number: 9840449
    Abstract: The invention relates to Guerbet alcohol precursors and Guerbet alcohols, as well as to processes for synthesizing them.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 12, 2017
    Assignee: P2 SCIENCE, INC.
    Inventors: Patrick Foley, Yonghua Yang
  • Patent number: 9822130
    Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: November 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Raphaelle Berger, Guizhen Dong, Subharekha Raghavan, Zhiqiang Yang
  • Patent number: 9808450
    Abstract: Provided herein are solid forms comprising (a) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (Lenalidomide) and (b) a coformer. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: November 7, 2017
    Assignee: Celgene Corporation
    Inventors: G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
  • Patent number: 9796664
    Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 24, 2017
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: James R. Rusche, Norton P. Peet, Allen Hopper
  • Patent number: 9796646
    Abstract: The present invention relates to a novel process for the preparation of 9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-ylamine which process comprises a) reacting cyclopentadiene in the presence of a radical initiator and CXCl3, wherein X is chloro or bromo, to a compound of formula II aa) reacting cyclopentadiene with CXCl3, wherein X is chloro, in the presence of a metal catalyst to a compound of formula II wherein X is chloro, b) reacting the compound of formula II with a base in the presence of an appropriate solvent to the compound of formula III c) and converting the compound of formula III in the presence of 1,2-dehydro-6-nitrobenzene to the compound of formula IV and d) hydrogenating the compound of formula IV in the presence of a metal catalyst.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: October 24, 2017
    Assignee: Syngenta Crop Protection, LLC
    Inventors: Denis Gribkov, Bjorn Antelmann, Fanny Giordano, Harald Walter, Alain De Mesmaeker
  • Patent number: 9789221
    Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: October 17, 2017
    Assignee: Mallinckrodt Pharma IP Trading D.A.C.
    Inventors: Ronald Dieck, Ian J. Handley, Neil Winterbottom, Joanna Wong
  • Patent number: 9782385
    Abstract: An artificial tears solution combination is composed mainly of an anti-inflammation and anti-oxidation material, a liquid viscosity-enhancing agent, and an artificial tears solution. The artificial tears solution combination is capable keeping moisture, and meanwhile having anti-inflammation and anti-oxidation capabilities. As such, it can prolong the liquid retention on ocular surfaces, to effective reduce the repeated dosing, and shorten the schedule for the dry eye syndrome.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: October 10, 2017
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Feng-Huei Lin, Hsu-Wei Fang, Ching-Li Tseng, Ya-Jung Hung
  • Patent number: 9782398
    Abstract: New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: October 10, 2017
    Assignee: Neurocrine Biosciences, Inc.
    Inventor: Samuel Roger Jesse Hoare
  • Patent number: 9782763
    Abstract: Disclosed herein is the use of manganese, iron, cobalt, or nickel complexes containing tridentate pyridine di-imine ligands as hydrosilylation catalysts. These complexes are effective for efficiently catalyzing hydrosilylation reactions, as well as offering improved selectivity and yield over existing catalyst systems.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: October 10, 2017
    Assignees: MOMENTIVE PERFORMANCE MATERIALS INC., PRINCETON UNIVERSITY
    Inventors: Keith James Weller, Crisita Carmen H. Atienza, Julie Boyer, Paul Chirik, Johannes G. P. Delis, Kenrick Lewis, Susan A. Nye
  • Patent number: 9775841
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: October 3, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant Kashinath Bhavar
  • Patent number: 9763870
    Abstract: The invention relates to formulations containing liquid ester quats and/or imidazolinium salts and polymer thickeners and to the use thereof.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 19, 2017
    Assignee: EVONIK DEGUSSA GMBH
    Inventors: Peter Schwab, Ursula Westerholt, Uta Kortemeier, Jochen Kleinen, Christian Hartung, Hans-Juergen Koehle
  • Patent number: 9751841
    Abstract: The present invention is a novel process for the preparation of chalcogenone compounds by conversion of ionic liquids and salts comprising nitrogen-containing heterocyclic cations and basic anions to the corresponding nitrogen-containing heterocyclic chalcogenones by reaction with elemental chalcogens.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: September 5, 2017
    Assignee: Petroliam Nasional Berhad
    Inventors: Robin Don Rogers, John Holbrey, Hector Rodriguez
  • Patent number: 9750716
    Abstract: The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders, vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 5, 2017
    Inventor: Wendy Anne Epstein
  • Patent number: 9744133
    Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: August 29, 2017
    Assignee: Pfizer Inc.
    Inventors: Gary Robert Agisim, Robert Alan Friedline, Shivangi Akash Patel, Cesar Ivan Sertzen, Vanessa Rose Shepperson
  • Patent number: 9744391
    Abstract: A method of implementing organic synthesis reactions uses a composition containing a metal catalyst originating from a calcined plant. The plants can be from the Brassicaceae, Sapotaceae and Convolvulaceae family, and the metal catalyst contains metal in the M(II) form such as zinc, nickel, manganese, lead, cadmium, calcium, magnesium or copper. Examples of the organic synthesis reactions include halogenations, electrophilic reactions, cycloadditions, transesterification reactions and coupling reactions, among others.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 29, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventors: Claude Grison, Jose Escarre
  • Patent number: 9744159
    Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 29, 2017
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During